Boston Scientific (0HOY) Share Forecast & Price Target

6 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0HOY Analyst Ratings

Moderate Buy

14 Buy

7 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Boston

Scientific

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0HOY Stock 12 Month Forecast

Average Price Target

$49.85

▲(4.01% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $49.85 with a high forecast of $60.00 and a low forecast of $44.00. The average price target represents a 4.01% change from the last price of $47.93.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"41":"$41","102":"$102","56.25":"$56.3","71.5":"$71.5","86.75":"$86.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$49.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$44.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[41,56.25,71.5,86.75,102],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.12,44.418461538461536,45.716923076923074,47.01538461538461,48.31384615384615,49.61230769230769,50.910769230769226,52.20923076923077,53.50769230769231,54.80615384615385,56.104615384615386,57.403076923076924,58.70153846153846,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.12,43.637692307692305,44.15538461538461,44.67307692307692,45.19076923076923,45.708461538461535,46.22615384615385,46.74384615384616,47.261538461538464,47.77923076923077,48.29692307692308,48.81461538461539,49.332307692307694,{"y":49.85,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.12,43.1876923076923,43.255384615384614,43.32307692307692,43.39076923076923,43.458461538461535,43.526153846153846,43.59384615384615,43.66153846153846,43.72923076923077,43.79692307692308,43.864615384615384,43.932307692307695,{"y":44,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":95.83,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.852,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.405,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.89,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.31,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 86,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.502,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 97,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.05,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 88,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.97,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.83,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.27,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.8,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.12,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$49.85

Lowest Price Target$44.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Christopher Pasquale

Barclays

$48→$45

Hold

-6.11%

Downside

Reiterated

10/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Universal Health (NYSE: UHS), Demant (Other OTC: WILLF) and Boston Scientific (NYSE: BSX)

Josh Jennings

TD Cowen

$56→$46

Hold

-4.03%

Downside

Downgraded

10/30/26

Boston Scientific downgraded to Hold from Buy at TD CowenBoston Scientific downgraded to Hold from Buy at TD Cowen

Travis Steed

Bank of America Securities

$54

Buy

12.66%

Upside

Reiterated

10/30/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and PTC Therapeutics (NASDAQ: PTCT)

Anthony Petrone

Mizuho Securities

$55→$50

Buy

4.32%

Upside

Reiterated

10/29/26

Boston Scientific price target lowered to $50 from $55 at MizuhoBoston Scientific price target lowered to $50 from $55 at Mizuho

Pito Chickering

Deutsche Bank

$60→$48

Buy

0.15%

Upside

Reiterated

10/29/26

Boston Scientific price target lowered to $48 from $60 at Deutsche BankBoston Scientific price target lowered to $48 from $60 at Deutsche Bank

Suraj Kalia

Oppenheimer

―

Hold

―

Downgraded

10/29/26

Boston Scientific downgraded to Perform from Outperform at OppenheimerBoston Scientific downgraded to Perform from Outperform at Oppenheimer

Mike Kratky

Leerink Partners

$55→$50

Buy

4.32%

Upside

Reiterated

10/29/26

Boston Scientific price target lowered to $50 from $55 at LeerinkBoston Scientific price target lowered to $50 from $55 at Leerink

William Plovanic

Canaccord Genuity

$66→$48

Buy

0.15%

Upside

Reiterated

10/29/26

Boston Scientific price target lowered to $48 from $66 at CanaccordBoston Scientific price target lowered to $48 from $66 at Canaccord

David Rescott

Robert W. Baird

$50→$51

Buy

6.41%

Upside

Reiterated

10/29/26

Boston Scientific price target raised to $51 from $50 at BairdBoston Scientific price target raised to $51 from $50 at Baird

Joanne Wuensch

Citi

$48→$44

Hold

-8.20%

Downside

Assigned

10/29/26

Boston Scientific price target lowered to $44 from $48 at CitiBoston Scientific price target lowered to $44 from $48 at Citi

Patrick Wood

UBS

$67→$57

Buy

18.92%

Upside

Assigned

10/29/26

Boston Scientific (BSX) Receives a Buy from UBS

Lee Hambright

Bernstein

$54→$49

Buy

2.23%

Upside

Reiterated

10/29/26

Analysts Offer Insights on Healthcare Companies: Encompass Health (NYSE: EHC), Boston Scientific (NYSE: BSX) and NeoGenomics (NASDAQ: NEO)

Matthew Taylor

Jefferies

$60→$46

Hold

-4.03%

Downside

Downgraded

10/28/26

Boston Scientific downgraded to Hold from Buy at JefferiesBoston Scientific downgraded to Hold from Buy at Jefferies

Robbie Marcus

J.P. Morgan

$46

Hold

-4.03%

Downside

Downgraded

10/28/26

Boston Scientific downgraded to Neutral from Overweight at JPMorganBoston Scientific downgraded to Neutral from Overweight at JPMorgan

Michael Matson

Needham

$57→$48

Buy

0.15%

Upside

Reiterated

10/28/26

Boston Scientific price target lowered to $48 from $57 at NeedhamBoston Scientific price target lowered to $48 from $57 at Needham

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Christopher Pasquale

Barclays

$48→$45

Hold

-6.11%

Downside

Reiterated

10/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Universal Health (NYSE: UHS), Demant (Other OTC: WILLF) and Boston Scientific (NYSE: BSX)

Josh Jennings

TD Cowen

$56→$46

Hold

-4.03%

Downside

Downgraded

10/30/26

Boston Scientific downgraded to Hold from Buy at TD CowenBoston Scientific downgraded to Hold from Buy at TD Cowen

Travis Steed

Bank of America Securities

$54

Buy

12.66%

Upside

Reiterated

10/30/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and PTC Therapeutics (NASDAQ: PTCT)

Anthony Petrone

Mizuho Securities

$55→$50

Buy

4.32%

Upside

Reiterated

10/29/26

Boston Scientific price target lowered to $50 from $55 at MizuhoBoston Scientific price target lowered to $50 from $55 at Mizuho

Pito Chickering

Deutsche Bank

$60→$48

Buy

0.15%

Upside

Reiterated

10/29/26

Boston Scientific price target lowered to $48 from $60 at Deutsche BankBoston Scientific price target lowered to $48 from $60 at Deutsche Bank

Suraj Kalia

Oppenheimer

―

Hold

―

Downgraded

10/29/26

Boston Scientific downgraded to Perform from Outperform at OppenheimerBoston Scientific downgraded to Perform from Outperform at Oppenheimer

Mike Kratky

Leerink Partners

$55→$50

Buy

4.32%

Upside

Reiterated

10/29/26

Boston Scientific price target lowered to $50 from $55 at LeerinkBoston Scientific price target lowered to $50 from $55 at Leerink

William Plovanic

Canaccord Genuity

$66→$48

Buy

0.15%

Upside

Reiterated

10/29/26

Boston Scientific price target lowered to $48 from $66 at CanaccordBoston Scientific price target lowered to $48 from $66 at Canaccord

David Rescott

Robert W. Baird

$50→$51

Buy

6.41%

Upside

Reiterated

10/29/26

Boston Scientific price target raised to $51 from $50 at BairdBoston Scientific price target raised to $51 from $50 at Baird

Joanne Wuensch

Citi

$48→$44

Hold

-8.20%

Downside

Assigned

10/29/26

Boston Scientific price target lowered to $44 from $48 at CitiBoston Scientific price target lowered to $44 from $48 at Citi

Patrick Wood

UBS

$67→$57

Buy

18.92%

Upside

Assigned

10/29/26

Boston Scientific (BSX) Receives a Buy from UBS

Lee Hambright

Bernstein

$54→$49

Buy

2.23%

Upside

Reiterated

10/29/26

Analysts Offer Insights on Healthcare Companies: Encompass Health (NYSE: EHC), Boston Scientific (NYSE: BSX) and NeoGenomics (NASDAQ: NEO)

Matthew Taylor

Jefferies

$60→$46

Hold

-4.03%

Downside

Downgraded

10/28/26

Boston Scientific downgraded to Hold from Buy at JefferiesBoston Scientific downgraded to Hold from Buy at Jefferies

Robbie Marcus

J.P. Morgan

$46

Hold

-4.03%

Downside

Downgraded

10/28/26

Boston Scientific downgraded to Neutral from Overweight at JPMorganBoston Scientific downgraded to Neutral from Overweight at JPMorgan

Michael Matson

Needham

$57→$48

Buy

0.15%

Upside

Reiterated

10/28/26

Boston Scientific price target lowered to $48 from $57 at NeedhamBoston Scientific price target lowered to $48 from $57 at Needham

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ARDXArdelyx

PVLAPalvella Therapeutics

CELCCelcuity

AMRXAmneal Pharmaceuticals

DNTHDianthus Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Boston Scientific

3 Months

Jayson BedfordRaymond James

Success Rate

34/53 ratings generated profit

Average Return

+3.21%

Copying Jayson Bedford's trades and holding each position for 3 Months would result in 64.15% of your transactions generating a profit, with an average return of +3.21% per trade.

1 Year

Jayson BedfordRaymond James

Success Rate

39/53 ratings generated profit

Average Return

+12.11%

Copying Jayson Bedford's trades and holding each position for 1 Year would result in 73.58% of your transactions generating a profit, with an average return of +12.11% per trade.

2 Years

Jayson BedfordRaymond James

Success Rate

41/53 ratings generated profit

Average Return

+22.73%

Copying Jayson Bedford's trades and holding each position for 2 Years would result in 77.36% of your transactions generating a profit, with an average return of +22.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HOY Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0HOY has received 38 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. 0HOY average Analyst price target in the past 3 months is 49.85.

Each month's total comprises the sum of three months' worth of ratings.

0HOY Financial Forecast

0HOY Earnings Forecast

Next quarter’s earnings estimate for 0HOY is $0.78 with a range of $0.77 to $0.83. The previous quarter’s EPS was $0.73. 0HOY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HOY has Performed in-line its overall industry.

0HOY Sales Forecast

Next quarter’s sales forecast for 0HOY is $5.21B with a range of $5.14B to $5.47B. The previous quarter’s sales results were $5.14B. 0HOY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HOY has Performed in-line its overall industry.

0HOY Stock Forecast FAQ

What is GB:0HOY’s average 12-month price target, according to analysts?

Based on analyst ratings, Boston Scientific’s 12-month average price target is 49.85.

What is GB:0HOY’s upside potential, based on the analysts’ average price target?

Boston Scientific has 4.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Boston Scientific a Buy, Sell or Hold?

Boston Scientific has a consensus rating of Moderate Buy, which is based on 14 buy ratings, 7 hold ratings and 0 sell ratings.

What is Boston Scientific’s share price target?

The average share price target for Boston Scientific is 49.85. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $60.00 ,and the lowest forecast is $44.00. The average share price target represents 4.01% Increase from the current price of $47.93.

What do analysts say about Boston Scientific?

Boston Scientific’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Boston Scientific?

To buy shares of GB:0HOY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Boston Scientific (0HOY) Share Forecast & Price Target

0HOY Analyst Ratings

0HOY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Boston Scientific

0HOY Analyst Recommendation Trends

0HOY Financial Forecast

0HOY Earnings Forecast

0HOY Sales Forecast

0HOY Stock Forecast FAQ

Detailed List of Analyst Forecasts